Ruxolitinib 5 MG BID Oral Tablet
IIT2023011-EC-2
Phase 2 small_molecule active
Quick answer
Ruxolitinib 5 MG BID Oral Tablet for The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active